From randomised controlled trials to real-world data: Clinical evidence to guide management of diabetic macular oedema

Archive ouverte

Gabrielle, Pierre-Henry | Mehta, Hemal | Barthelmes, Daniel | Daien, Vincent | Nguyen, Vuong | Gillies, Mark, C | Creuzot‐Garcher, Catherine

Edité par CCSD ; Elsevier -

Correspondence to: catherine.creuzot-garcher@chu-dijon.fr. International audience. Randomised clinical trials (RCTs) are generally considered the gold-standard for providing scientific evidence for treatments' effectiveness and safety but their findings may not always be generalisable to the broader population treated in routine clinical practice. RCTs include highly selected patient populations that fit specific inclusion and exclusion criteria. Although they may have a lower level of certainty than RCTs on the evidence hierarchy, real-world data (RWD), such as observational studies, registries and databases, provide real-world evidence (RWE) that can complement RCTs. For example, RWE may help satisfy requirements for a new indication of an already approved drug and help us better understand long-term treatment effectiveness, safety and patterns of use in clinical practice. Many countries have set up registries, observational studies and databases containing information on patients with retinal diseases, such as diabetic macular oedema (DMO). These DMO RWD have produced significant clinical evidence in the past decade that has changed the management of DMO. RWD and medico-administrative databases are a useful resource to identify low frequency safety signals. They often have long-term follow-up with a large number of patients and minimal exclusion criteria. We will discuss improvements in healthcare information exchange technologies, such as blockchain technology and FHIR (Fast Healthcare Interoperability Resources), which will connect and extend databases already available. These registries can be linked with existing or emerging retinal imaging modalities using artificial intelligence to aid diagnosis, treatment decisions and provide prognostic information. The results of RCTs and RWE are combined to provide evidence-based guidelines.

Suggestions

Du même auteur

Tout savoir sur le treat and extend : organisation et optimisation. Les Cahiers d'Ophtalmologie

Archive ouverte | Carré, Chloé | CCSD

National audience. La dégénérescence maculaire liée à l’âge (DMLA) est actuellement la première cause de handicap visuel dans les pays développés chez les plus de 50 ans. Elle touche en effet environ 8% de la popula...

Can high-dose aflibercept satisfy unmet treatment needs in diabetic macular oedema?

Archive ouverte | Gabrielle, Pierre-Henry | CCSD

Corresponding author: catherine.creuzot-garcher@chu-dijon.fr. International audience. Refers toIntravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non...

Oedème maculaire diabétique et membrane épirétinienne : quand opérer ?

Archive ouverte | Tessier, Mélanie | CCSD

National audience. L’oedème maculaire diabétique (OMD) est une des causes majeures de baisse d’acuité visuelle (BAV) chez les patients diabétiques et sa prise en charge est une problématique de notre pratique quotid...

Chargement des enrichissements...